Trials / Completed
CompletedNCT02738775
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ublituximab | Administered as an IV infusion. |
| DRUG | Placebo |
Timeline
- Start date
- 2016-05-27
- Primary completion
- 2017-09-27
- Completion
- 2018-08-13
- First posted
- 2016-04-14
- Last updated
- 2021-07-15
- Results posted
- 2021-07-15
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02738775. Inclusion in this directory is not an endorsement.